Oyster Point's OC-02 nasal spray meets in Phase IIb for dry eye

Oyster Point Pharma Inc. (Princeton, N.J.) said its OC-02 nasal spray met the primary endpoints in the double-blind, U.S. Phase IIb PEARL trial to treat dry eye disease. CEO Jeffrey Nau

Read the full 312 word article

User Sign In